Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.

Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM.

Radiother Oncol. 2018 Apr;127(1):43-48. doi: 10.1016/j.radonc.2018.02.002. Epub 2018 Mar 7.

PMID:
29525412
2.

MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy.

Gurney-Champion OJ, McQuaid D, Dunlop A, Wong KH, Welsh LC, Riddell AM, Koh DM, Oelfke U, Leach MO, Nutting CM, Bhide SA, Harrington KJ, Panek R, Newbold KL.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316. doi: 10.1016/j.ijrobp.2017.10.016. Epub 2017 Oct 16.

3.

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.

Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21.

4.

Survey on Paediatric Differentiated Thyroid Cancer Care in Europe.

Dekker BL, Newbold KL, F├╝hrer D, Waguespack SG, Handkiewicz-Junak D, Links TP; European Initiative on Collaboration on Paediatric Thyroid Cancer.

Horm Res Paediatr. 2018;89(1):58-62. doi: 10.1159/000484170. Epub 2017 Nov 17.

PMID:
29151082
5.

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.

J Clin Oncol. 2017 Aug 10;35(23):2692-2699. doi: 10.1200/JCO.2016.71.6472. Epub 2017 Jun 14.

PMID:
28613956
6.

Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.

Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d'Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL.

Clin Cancer Res. 2017 Aug 1;23(15):4233-4241. doi: 10.1158/1078-0432.CCR-16-1209. Epub 2017 Mar 17.

7.

The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Br J Radiol. 2017 Mar;90(1071):20160768. doi: 10.1259/bjr.20160768. Review.

8.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

9.

Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.

Newbold KL, Flux G, Wadsley J.

Clin Oncol (R Coll Radiol). 2017 May;29(5):307-309. doi: 10.1016/j.clon.2016.12.008. Epub 2017 Jan 27. Review.

PMID:
28139379
10.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

11.

Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.

Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):263-273. doi: 10.1016/j.clon.2016.12.001. Epub 2017 Jan 3.

12.

Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?

Panek R, Schmidt MA, Borri M, Koh DM, Riddell A, Welsh L, Dunlop A, Powell C, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO.

Med Phys. 2016 Nov;43(11):6024.

PMID:
27806585
13.

Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy.

Dean JA, Wong KH, Gay H, Welsh LC, Jones AB, Schick U, Oh JH, Apte A, Newbold KL, Bhide SA, Harrington KJ, Deasy JO, Nutting CM, Gulliford SL.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):820-831. doi: 10.1016/j.ijrobp.2016.08.013. Epub 2016 Aug 22.

14.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM.

BMC Cancer. 2016 Oct 6;16(1):770.

15.

Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.

Bhide SA, Thway K, Lee J, Wong K, Clarke P, Newbold KL, Nutting CM, Harrington KJ.

Br J Cancer. 2016 Sep 27;115(7):825-30. doi: 10.1038/bjc.2016.266. Epub 2016 Sep 1.

16.

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.

Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, Newbold KL, Bhide S, Harrington KJ.

Mol Cancer Ther. 2016 Sep;15(9):2042-54. doi: 10.1158/1535-7163.MCT-15-0998. Epub 2016 Jul 15.

17.

The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.

Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL.

J Nucl Med. 2016 Dec;57(12):1843-1850. Epub 2016 Jul 14.

18.

A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.

Wong KH, Kuciejewska A, Sharabiani MTA, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Radiother Oncol. 2017 Feb;122(2):207-211. doi: 10.1016/j.radonc.2016.06.015. Epub 2016 Jul 5.

PMID:
27393218
19.

Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers : Dosimetry and NTCP.

McQuaid D, Dunlop A, Nill S, Franzese C, Nutting CM, Harrington KJ, Newbold KL, Bhide SA.

Strahlenther Onkol. 2016 Aug;192(8):516-25. doi: 10.1007/s00066-016-0980-1. Epub 2016 Jun 13.

PMID:
27295511
20.

Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.

Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Radiother Oncol. 2016 Jul;120(1):21-7. doi: 10.1016/j.radonc.2016.05.015. Epub 2016 May 27.

21.

Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies.

Richards TM, Bhide SA, Miah AB, Del Rosario L, Bodla S, Thway K, Gujral DM, Rooney KP, Schick U, McGovern T, Grove L, Newbold KL, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e77-84. doi: 10.1016/j.clon.2016.04.035. Epub 2016 May 11.

22.

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.

Miah AB, Gulliford SL, Morden J, Newbold KL, Bhide SA, Zaidi SH, Hall E, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e69-76. doi: 10.1016/j.clon.2016.02.009. Epub 2016 Mar 17.

23.

Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.

Dean JA, Welsh LC, McQuaid D, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Newbold KL, Bhide SA, Harrington KJ, Gulliford SL, Nutting CM.

Radiother Oncol. 2016 Apr;119(1):166-71. doi: 10.1016/j.radonc.2016.02.022. Epub 2016 Mar 9.

24.

The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy.

Ng-Cheng-Hin B, Newbold KL.

Eur Endocrinol. 2016 Mar;12(1):39-43. doi: 10.17925/EE.2016.12.01.39. Epub 2016 Mar 15. Review.

25.

Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer.

Miah AB, Bhide SA, Del Rosario L, Matthews J, Nicol R, Tanay MA, Gupta S, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e61-7. doi: 10.1016/j.clon.2016.01.012. Epub 2016 Feb 11.

PMID:
26876458
26.

Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T.

Panek R, Welsh L, Dunlop A, Wong KH, Riddell AM, Koh DM, Schmidt MA, Doran S, Mcquaid D, Hopkinson G, Richardson C, Nutting CM, Bhide SA, Harrington KJ, Robinson SP, Newbold KL, Leach MO.

J Magn Reson Imaging. 2016 Jul;44(1):72-80. doi: 10.1002/jmri.25134. Epub 2016 Jan 22.

27.

Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data.

Borri M, Schmidt MA, Powell C, Koh DM, Riddell AM, Partridge M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO.

PLoS One. 2015 Sep 23;10(9):e0138545. doi: 10.1371/journal.pone.0138545. eCollection 2015.

28.

A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.

Miah AB, Schick U, Bhide SA, Guerrero-Urbano MT, Clark CH, Bidmead AM, Bodla S, Del Rosario L, Thway K, Wilson P, Newbold KL, Harrington KJ, Nutting CM.

Br J Cancer. 2015 Jan 6;112(1):32-8. doi: 10.1038/bjc.2014.553. Epub 2014 Dec 4.

29.

Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers.

Gujral DM, Miah AB, Bodla S, Richards TM, Welsh L, Schick U, Powell CJ, Clark CH, Bidmead MA, Grove L, Guerrero-Urbano T, Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Oral Oncol. 2014 Nov;50(11):1089-97. doi: 10.1016/j.oraloncology.2014.07.018. Epub 2014 Sep 6.

PMID:
25200524
30.

Neurocognitive function after (chemo)-radiotherapy for head and neck cancer.

Welsh LC, Dunlop AW, McGovern T, McQuaid D, Dean JA, Gulliford SL, Bhide SA, Harrington KJ, Nutting CM, Newbold KL.

Clin Oncol (R Coll Radiol). 2014 Dec;26(12):765-75. doi: 10.1016/j.clon.2014.06.014. Epub 2014 Jul 11. Review.

PMID:
25028338
31.

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial.

Gujral DM, Piercy D, Morden JP, Emson M, Hall E, Miah AB, Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Oral Oncol. 2014 Feb;50(2):141-6. doi: 10.1016/j.oraloncology.2013.10.012. Epub 2013 Nov 18.

PMID:
24263110
32.

Dose-response analysis of parotid gland function: what is the best measure of xerostomia?

Miah AB, Gulliford SL, Clark CH, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Radiother Oncol. 2013 Mar;106(3):341-5. doi: 10.1016/j.radonc.2013.03.009. Epub 2013 Apr 6.

PMID:
23566529
33.

The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT.

Miah AB, Gulliford SL, Bhide SA, Zaidi SH, Newbold KL, Harrington KJ, Nutting CM.

Radiother Oncol. 2013 Mar;106(3):346-51. doi: 10.1016/j.radonc.2013.03.006. Epub 2013 Mar 26.

PMID:
23540553
34.

Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer.

Powell C, Schmidt M, Borri M, Koh DM, Partridge M, Riddell A, Cook G, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Radiother Oncol. 2013 Jan;106(1):112-7. doi: 10.1016/j.radonc.2012.09.009. Epub 2012 Oct 22.

PMID:
23089306
35.

Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers.

Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Br J Radiol. 2012 May;85(1013):487-94. doi: 10.1259/bjr/85942136. Review.

36.

Prospective intra-patient evaluation of a shoulder retraction device for radiotherapy in head and neck cancer.

Newbold KL, Bhide S, Convery H, Harrington KJ, Nutting CM.

Med Dosim. 2012 Autumn;37(3):293-5. doi: 10.1016/j.meddos.2011.11.002. Epub 2012 Feb 22.

PMID:
22360837
37.

Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey.

Roe JW, Carding PN, Rhys-Evans PH, Newbold KL, Harrington KJ, Nutting CM.

Oral Oncol. 2012 Apr;48(4):343-8. doi: 10.1016/j.oraloncology.2011.11.003. Epub 2011 Nov 29.

PMID:
22130454
38.

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.

Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM.

Eur J Endocrinol. 2011 Aug;165(2):315-22. doi: 10.1530/EJE-11-0129. Epub 2011 May 12.

PMID:
21566072
39.

Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.

Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, Barbachano Y, A'hern R, Tanay M, Hickey J, Nicol R, Newbold KL, Harrington KJ, Nutting CM.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):539-47. doi: 10.1016/j.ijrobp.2010.09.055. Epub 2011 Jan 13.

PMID:
21236602
40.

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM.

Clin Cancer Res. 2010 Aug 1;16(15):4005-15. doi: 10.1158/1078-0432.CCR-10-0196.

41.

Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers.

Bhide SA, Newbold KL, Harrington KJ, Nutting CM.

Expert Rev Anticancer Ther. 2010 Mar;10(3):297-300. doi: 10.1586/era.10.15. No abstract available.

PMID:
20214509
42.

Radiation-induced xerostomia: pathophysiology, prevention and treatment.

Bhide SA, Miah AB, Harrington KJ, Newbold KL, Nutting CM.

Clin Oncol (R Coll Radiol). 2009 Dec;21(10):737-44. doi: 10.1016/j.clon.2009.09.002. Epub 2009 Oct 14. Review.

PMID:
19833490
43.

Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer.

Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, Nutting CM.

Acta Oncol. 2008;47(7):1229-36. doi: 10.1080/02841860802256483.

PMID:
18661420

Supplemental Content

Loading ...
Support Center